Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 11/2012

Open Access 01-11-2012 | Original Article

Pharmaceutical care for patients with breast and ovarian cancer

Authors: Andrea Liekweg, Martina Westfeld, Michael Braun, Oliver Zivanovic, Tania Schink, Walther Kuhn, Ulrich Jaehde

Published in: Supportive Care in Cancer | Issue 11/2012

Login to get access

Abstract

Purpose

Individualized patient care may help reduce the incidence of adverse drug events in systemic cancer therapy. This study was conducted to explore the feasibility and potential of additional pharmaceutical care for breast and ovarian cancer patients.

Methods

The study was designed as a prospective, multicentered cohort study with a control group. Ninety-eight breast or ovarian cancer patients were recruited from outpatient oncology clinics and primary care oncologists: initially into the control group receiving standard care and after implementation of pharmaceutical care into the intervention group consisting of additional patient counseling on the management of treatment-associated adverse events and optimization of supportive medication. Primary outcome was the complete response to the antiemetic prophylaxis. Secondary endpoints were the severity of nausea, frequency of emesis, health-related quality of life, and patient satisfaction with information on cancer treatment education.

Results

Forty-eight patients were included in the control group and 50 in the intervention group. Of the patients, 35.4% in the control group and 76.0% in the intervention group (p < 0.001) had a complete response to the antiemetic prophylaxis. The severity of acute and delayed nausea was not reduced. The global health scale and two symptom scales (nausea and vomiting, appetite loss) of the EORTC QLQ-C30 questionnaire were positively affected by pharmaceutical care. Patient satisfaction with information was significantly higher in the intervention group.

Conclusions

Patients with breast and ovarian cancer seem to benefit from pharmaceutical care, as suggested by improved patient-reported outcomes such as emetic episodes, quality of life, and patient satisfaction after implementation.
Appendix
Available only for authorised users
Literature
1.
Feyer P, Kleeberg UR, Steingraber M, Gunther W, Behrens M (2008) Frequency of side effects in outpatient cancer care and their influence on patient satisfaction—a prospective survey using the PASQOC questionnaire. Support Care Cancer 16:567–575PubMedCrossRef
2.
Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubinstein EB (2005) Rankings and symptom assessment of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227PubMedCrossRef
3.
Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK (2003) Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol 21:1373–1378PubMedCrossRef
4.
Norton PG, Baker GR (2007) Patient safety in cancer care: a time for action. J Natl Cancer Inst 99:579–580PubMedCrossRef
5.
Weingart SN, Cleary A, Seger A, Eng TK, Saadeh M, Gross A, Shulman LN (2007) Medication reconciliation in ambulatory oncology. Jt Comm J Qual Patient Saf 33:750–757PubMed
6.
Hepler CD, Strand LM (1990) Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 47:533–543PubMed
7.
Schwartz RN, Eng KJ, Frieze DA, Gosselin TK, Griffith N, Seung AH, Hinkel JM, Johnson PE, Johnson SA, Li EC, Szabatura AH, Wong MK (2010) NCCN Task Force Report: Specialty Pharmacy. J Natl Compr Canc Netw 8(Suppl 4):S1–S12PubMed
8.
Liekweg A, Westfeld M, Jaehde U (2004) From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care. Support Care Cancer 12:73–79PubMedCrossRef
9.
Skalla KA, Bakitas M, Furstenberg CT, Ahles T, Henderson JV (2004) Patients’ need for information about cancer therapy. Oncol Nurs Forum 31:313–319PubMedCrossRef
10.
Elf M, Wikblad K (2001) Satisfaction with information and quality of life in patients undergoing chemotherapy for cancer. The role of individual differences in information preference. Cancer Nurs 24:351–356PubMedCrossRef
11.
Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS, Reeve BB, Smith AW, Stone AA, Weinfurt K (2007) Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol 25:5106–5112PubMedCrossRef
12.
Basch E, Artz D, Dulko D, Scher K, Sabbatini P, Hensley M, Mitra N, Speakman J, McCabe M, Schrag D (2005) Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 23:3552–3561PubMedCrossRef
13.
Freidank A (1999) Schemata zur Prophylaxe von Zytostatika-induzierter Emesis und Nausea. Krankenhauspharmazie 20:49–54
14.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe P, Schraub S, Sneeuw K, Sullivan M, Takeda F, for the European Organisation for Research and Treatment of Cancer Study Group on Quality of Life (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef
15.
Fayers PM, Aaronson NK, Bjordal K, Curran D, Groenvold M (1999) The EORTC QLQ-C30 scoring manual. European Organization for Research and Treatment of Cancer, Brussels
16.
Liekweg A, Eckhardt M, Taylor SC, Erdfelder E, Jaehde U (2005) Psychometric assessment and application of a questionnaire measuring patient: satisfaction with information on cancer treatment. Pharm World Sci 27:96–103PubMedCrossRef
17.
Brunner E, Domhof S, Langer F (2001) Nonparametric analysis of longitudinal data in factorial experiments. Wiley, New York
18.
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M (2008) Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ 337:a1655PubMedCrossRef
19.
Doherty KM (1999) Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs 3:113–119PubMed
20.
American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947PubMedCrossRef
21.
Italian Group for Antiemetic Research (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 9:759–765CrossRef
22.
23.
Dranitsaris G, Warr D, Puodziunas A (1995) A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 3:183–189PubMedCrossRef
24.
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830PubMedCrossRef
25.
Jahn P, Renz P, Stukenkemper J, Book K, Kuss O, Jordan K, Horn I, Thoke-Colberg A, Schmoll HJ, Landenberger M (2009) Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. Support Care Cancer 17:1543–1552PubMedCrossRef
26.
Ravens-Sieberer U (2002) Measuring and monitoring quality-of-life in population surveys: still a challenge for public health research. Soz Praventivmed 47:203–204PubMed
27.
Boehmer S, Luszczynska A (2006) Two kinds of items in quality of life instruments: ‘indicator and causal variables’ in the EORTC qlq-c30. Qual Life Res 15:131–141PubMedCrossRef
28.
Carver CS, Lehman JM, Michael HA (2003) Dispositional pessimism predicts illness-related disruption of social and recreational activities among breast cancer patients. J Pers Soc Psychol 84:813–821PubMedCrossRef
29.
Allison PJ, Guichard C, Gilain L (2000) A prospective investigation of dispositional optimism as a predictor of health-related quality of life in head and neck cancer patients. Qual Life Res 9:951–960PubMedCrossRef
30.
Brenes GA, Rapp SR, Rejeski WJ, Miller ME (2002) Do optimism and pessimism predict physical functioning? J Behav Med 25:219–231PubMedCrossRef
31.
Schou I, Ekeberg O, Ruland CM (2005) The mediating role of appraisal and coping in the relationship between optimism-pessimism and quality of life. Psychooncology 14:718–727PubMedCrossRef
32.
Luker KA, Beaver K, Leinster SJ, Owens RG (1996) Information needs and sources of information for women with breast cancer: a follow-up study. J Adv Nurs 23:487–495PubMedCrossRef
33.
Adams M (1991) Information and education across the phases of cancer care. Semin Oncol Nurs 7:105–111PubMedCrossRef
34.
Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J (2001) Influence of context effects on health outcomes: a systematic review. Lancet 357:757–762PubMedCrossRef
35.
Campbell M, Donner A, Klar N (2007) Developments in cluster randomized trials and Statistics in Medicine. Stat Med 26:2–19PubMedCrossRef
Metadata
Title
Pharmaceutical care for patients with breast and ovarian cancer
Authors
Andrea Liekweg
Martina Westfeld
Michael Braun
Oliver Zivanovic
Tania Schink
Walther Kuhn
Ulrich Jaehde
Publication date
01-11-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 11/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1385-z

Other articles of this Issue 11/2012

Supportive Care in Cancer 11/2012 Go to the issue

Original Article

Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial

Original Article

Dietary energy density is associated with energy intake in palliative care cancer patients

Original Article

Symptom clusters in patients with bone metastases—a reanalysis comparing different statistical methods

Original Article

Effect of gamma radiation on bonding to human enamel and dentin

Original Article

Computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice

Original Article

Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits